Your browser is no longer supported. Please, upgrade your browser.
PJP PowerShares Dynamic Pharmaceuticals ETF daily Stock Chart
PowerShares Dynamic Pharmaceuticals ETF
Index- P/E- EPS (ttm)- Insider Own- Shs Outstand- Perf Week-0.63%
Market Cap- Forward P/E- EPS next Y- Insider Trans- Shs Float- Perf Month3.44%
Income- PEG- EPS next Q- Inst Own- Short Float- Perf Quarter-2.40%
Sales- P/S- EPS this Y- Inst Trans- Short Ratio0.14 Perf Half Y3.14%
Book/sh- P/B- EPS next Y- ROA- Target Price- Perf Year9.30%
Cash/sh- P/C- EPS next 5Y- ROE- 52W Range57.93 - 71.42 Perf YTD0.70%
Dividend0.46 P/FCF- EPS past 5Y- ROI- 52W High-9.52% Beta-
Dividend %0.71% Quick Ratio- Sales past 5Y- Gross Margin- 52W Low11.56% ATR0.75
Employees- Current Ratio- Sales Q/Q- Oper. Margin- RSI (14)61.39 Volatility0.95% 1.24%
OptionableYes Debt/Eq- EPS Q/Q- Profit Margin- Rel Volume0.46 Prev Close64.73
ShortableYes LT Debt/Eq- Earnings- Payout- Avg Volume38.36K Price64.62
Recom- SMA202.72% SMA503.05% SMA2000.72% Volume17,520 Change-0.17%
May-18-18 08:15AM  Who Are Projprzem SA.s (WSE:PJP) Major Shareholders? Simply Wall St.
May-11-18 04:18PM  6 Top Healthcare ETFs Rally as Trump Vows End to Global Freeloading ETF Trends
May-10-18 11:03AM  Does Projprzem SA.s (WSE:PJP) PE Ratio Signal A Buying Opportunity? Simply Wall St.
Apr-24-18 06:41AM  Should You Invest in the VanEck Vectors Pharmaceutical ETF (PPH)? Zacks
Apr-20-18 12:38PM  Projprzem SA. (WSE:PJP) Delivered A Better ROE Than The Industry, Heres Why Simply Wall St.
Apr-13-18 09:15AM  Is Projprzem SA. (WSE:PJP) A Financially Sound Company? Simply Wall St.
Mar-24-18 10:47AM  How to Invest in Healthcare Stocks the Easy Way Motley Fool
Feb-01-18 06:00AM  Top 5 Pharmaceutical ETFs for 2018 Investopedia
Jan-23-18 01:12PM  Vermont Legalizes Recreational Marijuana on January 22, 2018 Market Realist
Jan-18-18 10:30AM  A Look into Amgens Collaborations in 2H17 Market Realist
Nov-22-17 10:31AM  Mercks Immunology and Oncology Drugs, Post-3Q17 Market Realist
Nov-13-17 03:03PM  What Led to the Rise in the US Trade Deficit in September? Market Realist
Oct-30-17 12:25PM  Top 3 Pharmaceutical ETFs of 2017 Investopedia
Sep-12-17 07:37AM  How Mercks Diabetes Portfolio Performed in 2Q17 Market Realist
Sep-08-17 07:37AM  Why Jazz Pharmaceuticals Vyxeos Could Boost Revenue Growth in 2018 Market Realist
Sep-05-17 09:06AM  Eli Lilly & Co.s Recent Developments after Its 2Q17 Earnings Market Realist
Sep-01-17 10:37AM  Performance of Eli Lillys Endocrine Franchise in 2Q17 Market Realist
10:36AM  How Pfizers Enbrel and Xeljanz Are Positioned after 2Q17 Market Realist
07:36AM  Ligand Pharmaceuticals Focuses on Increasing Returns for Shareholders Market Realist
07:36AM  A Post-2Q17 Look at Pfizers Internal Medicines Market Realist
Aug-31-17 01:39PM  Why $475,000 isn't actually that expensive for Novartis's new drug Yahoo Finance
01:05PM  Why a $475,000 drug price tag isn't expensive Yahoo Finance Video
07:36AM  Bristol-Myers Squibbs Immunoscience Products in 2Q17 Market Realist
Aug-30-17 02:27PM  Trump can lower U.S. drug prices by fixing NAFTA Yahoo Finance
Aug-28-17 09:06AM  A Look into Mercks Immunology and Oncology Portfolio Market Realist
Aug-23-17 11:54AM  What Jazz Pharmaceuticals Expects for Vyxeos Market Realist
Aug-22-17 09:07AM  How Allergans US Specialized Therapeutics Segment Performed in 2Q17 Market Realist
07:37AM  Behind Xyrems Solid Demand Trends in 2017 Market Realist
07:36AM  Eliquis and Sprycel Could Boost BMYs Revenue Growth in 2H17 Market Realist
Aug-17-17 07:36AM  How Amgens Nephrology Drugs Are Positioned after 2Q17? Market Realist
Aug-10-17 10:36AM  Celgenes Abraxane Continued Steady Growth in 2Q17 Market Realist
Aug-07-17 09:45AM  Q2 Earnings Fail to Impress Pharma ETF Zacks
Aug-04-17 01:57PM  Valeant Pharmaceuticals Intl Inc (VRX) Stock: Stupid Is as Stupid Does InvestorPlace
Aug-01-17 10:41AM  How Gilead Sciences HCV Franchise Is Positioned after 2Q17 Market Realist
09:09AM  Dupixent Could Substantially Drive Regenerons Growth Market Realist
Jul-31-17 04:36PM  Examining Bristol-Myers Squibbs Oncology Portfolios 2Q17 Market Realist
07:40AM  Eli Lilly in 2Q17: Humulin and Endocrine Products Market Realist
Jul-28-17 07:36AM  Behind Pfizers Legacy Established Products Performance in 2017 Market Realist
Jul-14-17 10:37AM  Behind Allergans Business Segments and Revenues Market Realist
Jul-10-17 03:10PM  What Lies Ahead for Pharma ETFs in Second Half 2017 Zacks
10:37AM  How Bristol-Myers Squibb Stock Has Performed in 2Q17 Market Realist
Jul-07-17 12:00PM  Improving Health for This Pharma ETF Investopedia
Jul-05-17 09:06AM  Johnson & Johnsons Consumer Business in 1Q17 Market Realist
Jul-03-17 12:25PM  Gordon Gekko was right: Stocks are now a zero-sum game Yahoo Finance
10:37AM  How Did Keytruda Perform in 1Q17? Market Realist
Jun-30-17 01:44PM  Why the US is losing the war on drug prices: trader Yahoo Finance
11:37AM  Stocks edge up as Q2 draws to a close Yahoo Finance
Jun-29-17 08:00AM  Trending: OPEC Fails to Scare Oil Short-Sellers ETF Database
Jun-27-17 10:36AM  A Look at Pfizers Revenue for 1Q17 Market Realist
Jun-23-17 01:36PM  Why investors flipped 180 on health care stocks today: NYSE trader Yahoo Finance Video
May-30-17 02:02PM  How Johnson & Johnsons Valuation Changed Post-1Q17 Market Realist
May-24-17 10:36AM  Performance of Mercks Diabetes Portfolio in 1Q17 Market Realist
May-11-17 10:36AM  Understanding Allergans Valuation after the 1Q17 Results Market Realist
May-03-17 02:58PM  Gilead Sciences Posts Mixed Q1 Results: ETFs in Focus Zacks
Apr-26-17 09:09AM  Bristol-Myers Squibbs 1Q17 Estimates: Virology Segment Market Realist
Apr-20-17 05:05PM  Johnson & Johnsons 1Q17 Segment-by-Segment Performance Market Realist
Apr-13-17 04:35PM  Johnson & Johnsons 1Q17 Estimates: Pharmaceuticals Segment Market Realist
Apr-11-17 07:36AM  Analyzing the Performance of Abbott Laboratories in 1Q17 Market Realist
Apr-07-17 06:59PM  ETF Flyers: Pharmaceuticals
03:05PM  Performance of Merck & Co. Stock in 1Q17 Market Realist
Apr-04-17 10:36AM  These Key Product Developments Could Help Pfizer Market Realist
10:36AM  These Key Product Developments Could Help Pfizer
Apr-03-17 10:37AM  Recent Developments at Eli Lilly Market Realist
10:37AM  Recent Developments at Eli Lilly
Mar-30-17 09:08AM  How Eli Lillys Business Segments Performed in 2016 Market Realist
09:08AM  How Eli Lillys Business Segments Performed in 2016
Mar-24-17 10:35AM  Bausch & Lomb Continues to be Key Growth Driver for Valeant Market Realist
10:35AM  Bausch & Lomb Continues to be Key Growth Driver for Valeant
Mar-23-17 09:06AM  New Product Launches May Boost Valeants Dermatology Revenue Market Realist
09:06AM  New Product Launches May Boost Valeants Dermatology Revenue
Mar-22-17 10:36AM  Relistor May Be Solid Growth Opportunity for Valeant in 2017 Market Realist
10:36AM  Relistor May Be Solid Growth Opportunity for Valeant in 2017
Mar-20-17 10:22AM  Trump, Biogen and Amgen Hammer Healthcare ETFs Zacks
10:22AM  Trump, Biogen and Amgen Hammer Healthcare ETFs
Mar-15-17 04:33PM  Should You Buy Pharma ETFs Now? Zacks
04:33PM  Should You Buy Pharma ETFs Now?
03:48PM  [$$] Drug Stocks Look Ready To Move Higher
03:48PM  [$$] Drug Stocks Look Ready To Move Higher at
Mar-09-17 04:09AM  Trumps Obamacare Lite presents opportunities and perils for investors at MarketWatch
Mar-08-17 10:07AM  Trump Tweet on Drug Pricing Hits Biotech and Pharma ETFs
Mar-03-17 03:35PM  How Mylans Europe Segment Performed
Mar-01-17 08:59AM  Hit ETFs & Stocks from the Top Sector of February
Feb-28-17 09:06AM  Eli Lilly & Co.s Recent Developments
Feb-22-17 10:37AM  Keytruda: Merck & Co.s Immuno-Oncology Blockbuster Drug
Feb-09-17 08:00AM  Trending: Financials Trade Sideways as Trump Prepares Dodd-Frank Rollback
Feb-06-17 09:55AM  Q4 Earnings Faring Well for Pharma ETFs
Feb-01-17 09:06AM  Changes in Bristol-Myers Squibbs 4Q16 Profitability
Jan-25-17 12:05PM  Why Eli Lilly Expects to See Revenue Growth in 4Q16
Jan-19-17 04:06PM  What Lies Ahead for Pharma ETFs?
08:00AM  Trending: Pound Gains as Theresa May Lays out Brexit Plan
Jan-13-17 07:36AM  Mylans Profit Margins: What Made Them Change?
Jan-12-17 07:37AM  Understanding Mylans Revenues
Jan-03-17 07:36AM  Harvoni: Gilead Sciences Blockbuster HCV Drug
Dec-12-16 11:06AM  How Could Pfizer Drive Growth for Ibrance?
Dec-07-16 09:44AM  Pisani: Trump rally is evolving
Dec-02-16 04:05PM  Two Nano-Cap Pharma Stocks To Watch Right Now at Insider Monkey
Dec-01-16 10:05AM  Understanding Mercks Most Recent Product Developments
08:05AM  How Baxter Continues to Contribute to Patient Care
Nov-30-16 08:05AM  Steady Rise: Allergans International Segment in 3Q16
Nov-29-16 11:04AM  How Did Gilead Sciencess HCV Business Perform across Geographies?
The investment seeks to track the investment results (before fees and expenses) of the Dynamic Pharmaceutical IntellidexSM Index. The fund generally will invest at least 90% of its total assets in common stocks of pharmaceutical companies that comprise the underlying intellidex. The underlying intellidex was composed of common stocks of 23 U.S. pharmaceuticals companies. These companies are engaged principally in the research, development, manufacture, sale or distribution of pharmaceuticals and drugs of all types. The fund is non-diversified.